Thanks
Rob
This email was sent from a mobile device with an annoyingly small keyboard, apologies for any typos
hVIVO is the new name of Retroscreen Virology! (from 15 April 2015). hVIVO is a rapidly growing UK life sciences company pioneering a technology platform which uses human challenge models of disease involving healthy volunteers to study new drugs and investigate disease in a safe, controlled, clinical environment. Our belief is that the best way to understand human disease is by studying it in humans, not laboratory models.
Tuesday 31 January 2012
Natural flu resistance discovery offers universal vaccine hope - Telegraph
http://www.telegraph.co.uk/health/healthnews/9051807/Natural-flu-resistance-discovery-offers-universal-vaccine-hope.html
Monday 30 January 2012
Wednesday 25 January 2012
Monday 16 January 2012
BBC E-mail: La Nina 'may abet' flu pandemics
Rob Lambkin-Williams BSc, PhD, MRPharmS
Chief Scientific Officer
Retroscreen Virology ltd
Chief Scientific Officer
Retroscreen Virology ltd
Sunday 1 January 2012
Cases of Tamiflu-resistant flu concern experts - USATODAY.com
http://yourlife.usatoday.com/health/story/2011-12-31/Cases-of-Tamiflu-resistant-flu-concern-experts/52290856/1
Rob_LW
Rob Lambkin-Williams BSc, PhD, MRPharmS
Chief Scientific Officer
Retroscreen Virology ltd
Rob_LW
Rob Lambkin-Williams BSc, PhD, MRPharmS
Chief Scientific Officer
Retroscreen Virology ltd
Subscribe to:
Posts (Atom)